Fig. 2

Construction and validation of the ARLnc predictive signature in STAD patients. Distribution of risk score, survival status, expression of four ARLncs in the high- and low- risk groups of STAD patients in the training cohort (A-C), and in the validation cohort; (F-H). Survival difference between high- and low-risk groups in the training cohort (D) and in the validation cohort (I); The AUCs for the ARLnc signature at 1-, 3-, and 5-year OS in the training (E) and validation cohort (J), respectively